Product logins

Find logins to all Clarivate products below.


VOYXACT® (sibeprenlimab)

Learn how VOYXACT is changing the immunoglobulin A nephropathy (IgAN) landscape.

What is sibeprenlimab (VOYXACT) and what sets it apart

VOYXACT, a first-in-class selective APRIL (A PRoliferation-Inducing Ligand) inhibitor, is positioned to be a high-impact, disease-modifying entrant in IgAN. It has demonstrated one of the most robust efficacy profiles in proteinuria reduction for IgAN thus far, as well as a well-established safety profile across dose ranges.

It targets a key IgAN pathogenic pathway to reduce galactose-deficient IgA1 (Gd-IgA1) production and subsequent immune complex formation, addressing the cause of disease progression. It represents a major commercial milestone for the company after it initiated the largest IgAN trial to date.

About VOYXACT

  • Company: Otsuka Pharmaceutical Co Ltd
  • Type: Monoclonal antibody targeting APRIL
  • Usage: Subcutaneous administration every 4 weeks to treat IgAN
    Also being evaluated to treat Sjögren’s syndrome
  • When will sibeprenlimab be available?
    Expected launch 2026: United States
    Expected launch 2028: Japan
    Expected launch 2029: European Union

VOYXACT sales and success forecasts

$955m
expected sales in the G7 markets in 2031
95%
probability of success for VOYXACT in the United States

There is very strong genetic support for this pathway. I think it is probably the most exciting pathway that is being targeted to address the primary disease mechanism. I'm very enthusiastic about it.

Nephrologist United States

Drugs in the 2026 list